A Randomized, Blinded, Placebo-Controlled Dose-Ranging Phase 1b Study of the Safety, Pharmacokinetics, and Antiviral Activity of ABI-4334 in Subjects with Chronic Hepatitis B Virus Infection
This research study is looking at a new potential medicine called ABI-4334 for people who have chronic (long-term) hepatitis B. Hepatitis B is a virus that can affect the liver. The main goals of this early-stage study are to see if ABI-4334 is safe for people to take, how it moves through and is processed by the body, and if it shows any signs of reducing the amount of virus. The study will test different doses of the medicine to find out which one might work best. Some participants will receive the new medicine, and others will receive a placebo (dummy drug) to compare the results. This helps researchers understand the true effects of the new treatment.
At a glance
What is this study about?
This study is about a new medicine, called ABI-4334, which is being developed for people who have chronic hepatitis B. Chronic hepatitis B means you have had the hepatitis B virus in your body for a long time. This virus can cause problems with your liver over many years, and doctors are always looking for better ways to treat it and stop it from causing serious damage.
In this early stage of research, the main things doctors want to find out are whether ABI-4334 is safe for people to take and how it behaves inside the body. They also want to see if there are any signs that it helps to reduce the amount of the hepatitis B virus. To do this, some people taking part in the study will receive the new medicine, and others will receive an inactive substance called a placebo. This helps researchers work out if any changes they see are because of the medicine itself.
The study will also test different amounts (doses) of ABI-4334 to find the dose that is most effective and gives the fewest side effects. This kind of study is a crucial first step in developing any new medicine. By carefully testing ABI-4334 now, researchers hope to gather important information that could lead to a new treatment option for chronic hepatitis B in the future.
Key takeaways
- This study is testing a new hepatitis B medicine called ABI-4334.
- It aims to find out if the medicine is safe and how it works in the body.
- Researchers will also look for early signs that it helps fight the virus.
- Different doses will be tested to find the best amount.
- It's an early-stage study for people with long-term hepatitis B.
- Participants will receive either the new medicine or a placebo.
Who may be eligible?
To join this study, you must be at least 18 years old. There's no upper age limit, so older adults can also take part if they meet other health requirements.
Both men and women are welcome to participate in the study. The researchers want to include a diverse group of people to see how the new medicine works across different individuals.
This study is specifically for people who have been diagnosed with chronic hepatitis B virus infection. This means you have had the hepatitis B virus for a long time. If you have other serious health problems, or are taking certain other medications, you might not be able to join. The study team will need to check your full medical history to confirm if you are suitable.
- Are you 18 years old or older?
- Do you have a diagnosis of chronic (long-term) hepatitis B virus infection?
- Are you able to attend regular clinic visits?
- Are you willing to potentially receive either the study medicine or a placebo?
- Are you willing to have regular blood tests and other check-ups?
This is a guide only — the research team will confirm whether you can take part.
What does participation involve?
Taking part in this study would involve several visits to a clinic or hospital over a period of time. You would be given either the new medicine, ABI-4334, or a placebo (a dummy pill with no active ingredient). Neither you nor the study doctors will know which you are receiving, which helps to keep the results fair and accurate.
During your visits, you'll have regular check-ups, which may include blood tests to monitor your health and how the medicine is affecting the virus. You might also have other tests to see how the medicine is working in your body and to check for any side effects. You'd need to follow specific instructions about taking your medicine and report any changes in your health to the study team. The full duration of your participation, and the number of visits, would be explained in detail by the study team.
Potential risks and benefits
Locations (2)
- —Bulgaria
- —Romania
Common questions
What is chronic hepatitis B?
Chronic hepatitis B means you have had the hepatitis B virus in your body for a long time, often for years. It can affect your liver and may need ongoing medical care.
What does 'dose-ranging' mean?
It means the study is testing different amounts of the medicine to find out which dose is safest and most effective in fighting the virus.
What is a 'placebo'?
A placebo is a 'dummy' pill or treatment that looks just like the real medicine but contains no active drug. It helps researchers compare the effects of the new medicine.
Will I know if I'm getting the real medicine or the placebo?
No, this study is 'blinded,' meaning neither you nor your study doctor will know whether you are receiving the active medicine or the placebo. This helps prevent bias.
Why is this study important if it's only Phase 1b?
Phase 1b studies are an early, crucial step to find out if a new medicine is safe for people, how it works in the body, and if it shows early signs of helping. This information is key before larger studies can happen.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.